Skip to content
drillr.ai
Sign up

688062.SH

迈威生物-U

SSE · Healthcare · Biotechnology · CN

CNY 29.23
−6.22%
Ask drillr

  • Aug 30, 2026, 07:55 UTC

    Mabwell Bioscience reported its H1 2026 semi-annual results on August 30, with revenue of 313 million yuan (up 209.04% year-on-year) and a net loss attributable to shareholders of 522 million yuan, narrowing from a loss of 551 million yuan in the same period last year.

    Source:

  • Jul 16, 2026, 02:21 UTC

    Mabwell (Shanghai) Bioscience Co., Ltd. received approval from the National Medical Products Administration for a clinical trial application of its 9MW5211 injection for vitiligo.

    Source: